Shares of Enlivex Therapeutics Ltd. (ENLV) are up more than 30% Monday morning, continuing the momentum following positive Covid-19 drug results.
On October 1, the company had reported positive top-line results from the study of its Covid-19 drug candidate, Allocetra.
The stock gained nearly 60% in the last two days.
Enlivex stock is currently trading at $14.12, nearing to its 52-week high of $16.94.
For comments and feedback contact: editorial@rttnews.com
Business News